Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

Stock Information for Akoya BioSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akoya BioSciences Inc.

Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive Oncology Closes Registered Direct Offering
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.